Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 with or without HLX10 + mFOLFOX6 in metastatic colorectal cancer
CTR20220362Phase 2Terminated
- Sponsor
- HyBioPharma
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab, serplulimab, mFOLFOX6 in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), sponsored by HyBioPharma. Started Apr 2022; status: terminated.
02
Drugs
pimurutamabserplulimabmFOLFOX6
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20220362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220362.